Tiger Brokers

BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept

Reuters
Feb 23
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept

Feb 23 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOP-LINE RESULTS FROM REGISTRATIONAL PHASE 2 STUDY OF LUSPATERCEPT IN ADULTS WITH ALPHA (Α)-THALASSEMIA

  • BRISTOL-MYERS SQUIBB CO - COHORTS MET PRIMARY AND SECONDARY ENDPOINTS

  • BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT INCREASE IN HEMOGLOBIN LEVELS

  • BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT DECREASE IN RBC TRANSFUSION BURDEN

  • BRISTOL-MYERS SQUIBB CO - SAFETY FINDINGS CONSISTENT WITH KNOWN PROFILE OF REBLOZYL IN THALASSEMIA

Source text: ID:nBwbFqRnta

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10